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Abstract
Plasma Epstein‐Barr virus (EBV) DNA measurement has established prognostic util-
ity in EBV‐driven lymphomas, where it serves as a circulating tumor DNA marker. 
The value of plasma EBV measurement may be amplified in sub‐Saharan Africa 
(SSA), where advanced imaging and molecular technologies for risk stratification are 
not typically available. However, its utility in diffuse large B‐cell lymphoma (DLBCL) 
is less certain, given that only a subset of DLBCLs are EBV‐positive. To explore this 
possibility, we measured plasma EBV DNA at diagnosis in a cohort of patients with 
DLBCL in Malawi. High plasma EBV DNA at diagnosis (≥3.0 log10 copies/mL) was 
associated with decreased overall survival (OS) (P = .048). When stratified by HIV 
status, the prognostic utility of baseline plasma EBV DNA level was restricted to HIV‐
positive patients. Unexpectedly, most HIV‐positive patients with high plasma EBV 
DNA at diagnosis had EBV‐negative lymphomas, as confirmed by multiple methods. 
Even in these HIV‐positive patients with EBV‐negative DLBCL, high plasma EBV 
DNA remained associated with shorter OS (P = .014). These results suggest that EBV 
reactivation in nontumor cells is a poor prognostic finding even in HIV‐positive pa-
tients with convincingly EBV‐negative DLBCL, extending the potential utility of EBV 
measurement as a valuable and implementable prognostic marker in SSA.
K E Y W O R D S
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1 |  INTRODUCTION
Epstein‐Barr virus (EBV) is an oncogenic herpesvirus 
implicated in many lymphomas, as well as some solid 
tumors.1 For a subset of lymphomas, such as endemic 
forms of Burkitt lymphoma, EBV is present in the tumor 
cells of nearly all cases.2 However, for other lymphomas, 
such as diffuse large B‐cell lymphoma (DLBCL), both 
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EBV‐negative and EBV‐positive forms of disease are rec-
ognized.3,4 The likelihood that a patient's DLBCL will be 
EBV‐associated is primarily related to underlying immune 
status, with human immunodeficiency virus (HIV) infec-
tion, iatrogenic immunosuppression, and advanced age all 
increasing the likelihood of EBV positivity.5
DLBCL is the most common subtype of lymphoma 
worldwide, and in sub‐Saharan Africa (SSA), the incidence 
of this and other aggressive B‐cell lymphomas is increas-
ing, primarily due to HIV and population aging.6-9 Prior 
studies have suggested EBV‐positivity in approximately 
80%‐90% of cases of HIV‐associated DLBCL with immu-
noblastic cytology and approximately 30% of cases with 
centroblastic cytology.5,10 By comparison, less than 10% of 
DLBCL arising in HIV‐negative individuals is associated 
with EBV.5
Accurate risk stratification of DLBCL remains chal-
lenging in low‐income countries, as there is generally no 
access to positron emission tomography (PET) scans, cell‐
of‐origin subtyping assays, or prognostically informative 
cytogenetic or immunophenotypic studies. While often 
under‐appreciated, risk stratification is critically important 
in these settings. Intensive chemotherapy is often associ-
ated with treatment‐related morbidity and mortality due 
to poor supportive care, conferring substantial risks to pa-
tients that may be more pronounced than in high‐income 
countries.
Plasma EBV measurement is a clinically valuable and 
highly implementable biomarker for many EBV‐associ-
ated malignancies.11-13 We and others have suggested that 
plasma EBV measurement may be particularly informative 
in SSA and other low‐income settings, where EBV‐associ-
ated lymphomas are common.14-16 This hypothesis has gen-
erally been confirmed for lymphomas that are invariably 
EBV‐positive, like endemic Burkitt lymphoma and HIV‐as-
sociated classic Hodgkin lymphoma.14,15,17,18 In such cases, 
plasma EBV functions as a sensitive circulating tumor DNA 
(ctDNA) marker, with both prognostic and monitoring util-
ity. Conversely, the value of plasma EBV measurement for 
DLBCL, which is EBV‐associated in a minority of cases, 
is less clear. We therefore sought to correlate pretreatment 
plasma EBV level with survival in a cohort of patients with 
DLBCL in Malawi.
2 |  METHODS
2.1 | Study participants
All patients included in this study were enrolled in the 
Kamuzu Central Hospital (KCH) Lymphoma Study. Details 
of this study have been described previously19,20; but briefly, 
the KCH Lymphoma Study is an ongoing prospective ob-
servational cohort based at a national teaching hospital in 
Lilongwe, Malawi. KCH is one of two referral centers for 
cancer care in Malawi, with a catchment area of approxi-
mately 9 million people.
For this analysis, all patients were adults (≥18  years) 
diagnosed with DLBCL between June 1, 2013 and May 31, 
2016. All DLBCL diagnoses were confirmed by tissue bi-
opsy, supported by manual immunohistochemistry (IHC) 
and a weekly clinicopathologic teleconference attended 
by pathologists and oncologists in the United States and 
Malawi.20 Subsequently, tissue blocks were sent to the 
University of North Carolina (UNC) at Chapel Hill for 
diagnostic confirmation and additional ancillary studies, 
as described previously and below.20 In addition to a con-
firmed diagnosis of DLBCL, the only other inclusion crite-
rion for this study was availability of a pretreatment plasma 
EBV level (see below).
First‐line chemotherapy for patients with DLBCL in this 
cohort was CHOP (cyclophosphamide, doxorubicin, vincris-
tine, prednisone), along with concurrent antiretroviral ther-
apy in HIV‐positive patients. All participants were followed 
until death, or administrative censoring on November 1, 
2018, with none lost to follow‐up.
2.2 | Plasma EBV measurement
Plasma EBV measurements were performed in the UNC 
Vironomics Core Facility, as previously described.14 Briefly, 
anti‐coagulated plasma was collected prior to initiation of 
cytotoxic chemotherapy and then stored at −80°C, prior to 
shipment to UNC. Quantitative plasma EBV measurement 
was performed using a quantitative real‐time polymerase 
chain reaction (qPCR) assay with primer pairs designed to 
amplify a conserved region of the EBV EBNA3C gene, cor-
responding to positions 88933‐89033 of the EBVI reference 
genome and positions 89374‐89836 of the EBVII reference 
genome. The linear detection range for this assay is 2.0‐8.0 
log10 copies/mL, with values <2.0 log10 copies/mL reported 
as “not detected”.
2.3 | Tumor EBV staining
EBV staining was performed on tissue blocks in the UNC 
Translational Pathology laboratory by three methods: 
EBER ISH (Novocastra EBER Probe; Leica Biosystems), 
LMP1 IHC (Abcam), and EBNA1 IHC (Novus USA). All 
stains were performed on a Leica Bond Max instrument, 
according to the manufacturer's instructions, with chromo-
genic detection via Leica Bond Polymer AP Red Detection 
Kit for ISH and Leica Bond Intense R Detection Kit sup-
plemented with Novocastra Novolink Polymer Detection 
System for IHC. Tumors were considered stain positive if at 
least 50% of the neoplastic cells were stained. Importantly, 
however, only a single negative case had between 1% and 
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50% positive cells (patient 25 in Table 3). In all cases, 
results were compared to appropriate controls, including 
confirmation of adequate RNA preservation for interpreta-
tion of negative EBER ISH (Epstein‐Barr encoded RNA in 
situ hybridization) stains.
2.4 | Tumor EBV polymerase chain reaction
DNA was extracted on a Maxwell® 16 MDx instrument 
(Promega) using 5 × 10 μm scrolls prepared from the diag-
nostic formalin‐fixed, paraffin embedded tissue block. Then, 
EBV was detected by a qPCR assay targeting the BamH1W 
segment of EBV, as previously described.21 Cases were con-
sidered positive if the fluorescence signal crossed the critical 
threshold in fewer than 40 cycles.
2.5 | Statistical analysis
Patient clinical characteristics were compared by Mann‐
Whitney U‐Test (for continuous data) or by Fisher Exact 
Test (categorical data). Survival curves were compared and 
hazard ratios were calculated by log rank test. All statistical 
analyses were performed using GraphPad Prism 8.
2.6 | Informed consent and IRB approval
Informed consent was obtained in English or Chichewa, the 
two national languages in Malawi. This study was approved 
by the UNC Institutional Review Board and the Malawi 
National Health Sciences Research Committee and is regis-
tered with clinicaltrials.gov under NCT02835911.
3 |  RESULTS
3.1 | Patients
A pretreatment plasma EBV measurement was available in 
44 patients diagnosed with DLBCL during the study period, 
including 25 HIV‐positive and 19 HIV‐negative individu-
als. Clinical characteristics of these patients, stratified by 
HIV status, are shown in Table 1. As in previous descrip-
tions of this cohort,19,22 HIV‐positive patients were younger 
than their HIV‐negative counterparts (45.4 vs 56.2  years, 
P  =  .03), with similar male predominance in both groups 
(19:6 vs 12:7, P = .51).
3.2 | Pretreatment plasma EBV 
measurements and survival
Pretreatment plasma EBV DNA level was also similar be-
tween HIV‐positive and HIV‐negative patients (median 2.81 
log10 copies/mL vs < 2.0, P =  .22, Table 1). In addition, a 
similar proportion of HIV‐positive and HIV‐negative pa-
tients had negative pretreatment plasma EBV DNA studies, 
falling below the assay's validated limit of detection of 2.0 
log10 copies/mL (10/25 vs 12/19, P = .22, Table 1). Amongst 
those patients with a positive plasma EBV result, the median 
pretreatment plasma EBV DNA level was similar in HIV‐
positive and HIV‐negative patients (3.91 vs 3.94, P  =  .70, 
data not shown). Finally, there was also no difference in the 
fraction of HIV‐positive vs HIV‐negative patients with a 
“high” pretreatment plasma EBV DNA level, defined here as 
≥3.0 log10 copies/mL (10/25 vs 6/19, P = .75). This “high” 
threshold was chosen to define a cutpoint robustly above the 
limit of detection and above the level typically seen in cancer 
patients with non‐EBV‐associated tumors.23
Next, we sought to determine whether pretreatment EBV 
DNA level was correlated with outcomes in Malawian pa-
tients with DLBCL. First, we evaluated all study participants, 
irrespective of HIV status. In the full cohort, high pretreat-
ment plasma EBV DNA was correlated with a significant 
decrease in overall survival (OS) (P  =  .048 and hazard 
ratio = 2.1, 95% CI = 0.9‐4.8) (Figure 1A).
In order to determine whether the survival disadvantage 
of a high pretreatment plasma EBV level might be related 
to HIV status, HIV‐negative and HIV‐positive patients were 
T A B L E  1  Clinical characteristics and pretreatment plasma EBV DNA level of all DLBCL patients
  All patients (n = 44) HIV pot (n = 25) HIV neg (n = 19) P value
Age, median years (range) 47.1 (23.2‐77.4) 45.4 (24.1‐63.2) 56.2 (23.2 ‐77.4) .03
Male:female 31:13 19:6 12:7 .51
EBV log10 copies/mL at diagnosis, median (range) 2.81 (<2.0‐7.11) 2.81 (<2.0‐6.36) <2.0 (<2.0‐7.11) .22
Patients with plasma EBV at diagnosis below LOD, 
n (%)
22 (50) 10 (40) 12 (63) .22
Patients with EBV log10 > 3.0 copies/mL at diagnosis 
(%)
16 (36) 10 (40) 6 (32) .75
Tumor EBV positive by EBER in situ hybridization/
total (%)
5/42 (11)* 2/23 (9)* 3/19 (19) .64
Abbreviations: EBER, EBV encoded RNA; EBV, Epstein‐Barr virus; LOD, limit of detection.
*EBER ISH results were uninterpretable in two HIV‐positive lymphomas due to failed RNA preservation. 
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analyzed separately. Whereas there was no correlation be-
tween pretreatment plasma EBV DNA level and survival in 
HIV‐negative patients (Figure 1B, P =  .67), high pretreat-
ment plasma EBV DNA was associated with markedly shorter 
OS in HIV‐positive patients (Figure 1C, P  =  .005, hazard 
ratio = 3.8, 95% CI = 1.1‐12.5). Emphasizing the relation-
ship between pretreatment plasma EBV level and survival in 
HIV‐positive patients, the median OS for patients with high 
pretreatment plasma EBV DNA was just 16 days, compared 
to 1534 days for patients with low pretreatment plasma EBV 
DNA (Table 2, P = .005). In addition, all HIV‐positive pa-
tients who died in the first 100 days after diagnosis had a 
pretreatment plasma EBV level ≥3.0 log10 copies/mL (Table 
2, P = .0002), despite having similar CD4 counts at DLBCL 
diagnosis (198 ± 178 × 109/L in patients dying in <100 days 
vs 173 ± 154 × 109/L in patients living > 100 days, P = .83).
HIV‐positive patients with high pretreatment plasma EBV 
were also more likely to have Eastern Cooperative Oncology 
Group (ECOG) performance status ≥2 and Ann Arbor Stage 
IV disease (Table 2, P = .002 and P = .049 respectively). In 
addition, the ratio of patient lactate dehydrogenase (LDH) 
to the laboratory's upper limit of normal was higher in HIV‐
positive patients with a high pretreatment EBV level, though 
there was no difference in the fraction of patients with an el-
evated LDH between HIV‐positive and HIV‐negative groups 
(Table 2, P = .02 and P = 1.0, respectively). Both interna-
tional prognostic index score and age‐adjusted international 
prognostic index score tended to be higher in HIV‐positive 
F I G U R E  1  Pretreatment plasma EBV DNA level and overall survival in patients with DLBCL in Malawi. A, All patients with DLBCL; B, 
HIV‐negative patients with DLBCL; C, HIV‐positive patients with DLBCL; and D, HIV‐positive patients with tumors that are EBV negative by 
EBER ISH, LMP1 IHC, EBNA1 IHC, and tissue PCR (“quadruple negative.”). For all plots, patients were stratified by pretreatment plasma EBV 
DNA levels: <3.0 log10 copies/ mL (blue) or ≥3.0 log10 copies/mL (red). P values and hazard ratios with 95% confidence intervals, as determined 
by log rank test, are shown
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patients with a high pretreatment EBV level, though these 
differences were not statistically significant (P  =  .09 and 
0.12, respectively). Finally, there were no differences in mean 
age, gender, time since HIV diagnosis, CD4 count, HIV viral 
load, peripheral white blood cell count, antiretroviral therapy 
(ART) status if HIV‐positive, or treatment‐related mortality 
between patients with a high or low pretreatment plasma 
EBV level (Table 2).
3.3 | Correlation between tumor EBER 
ISH and plasma EBV detection
To determine whether the high plasma EBV detected in some 
patients correlated with EBV status in the tumor, we evalu-
ated tumor EBV status by EBER ISH. Interpretable EBER 
ISH results were available on 42/44 patients. Images of rep-
resentative lymphomas from patients in this cohort are shown 
in Figure 2. A similar proportion of DLBCLs were EBER 
ISH positive in HIV‐positive (2/23, 9%) and HIV‐negative 
(3/19, 16%) patients, with 4/5 positive cases occurring in in-
dividuals 54 years of age or older, including all 3 HIV‐nega-
tive cases (Table 1, data not shown). Amongst HIV positive 
cases, there were too few EBER‐positive DLBCLs to make 
meaningful clinical comparisons between EBER‐positive 
(n = 2) and EBER‐negative cases (n = 21). However, there 
was no obvious difference in mean CD4 count between these 
groups (105  ±  78  ×  109/L in EBER‐positive DLBCL vs 
179 ± 154 × 109/L in EBER‐negative DLBCL).
Notably, tumor EBER‐positive cases in the cohort (n = 5) 
were substantially less numerous than cases with a high pre-
treatment plasma EBV DNA level (n  =  16). While 3 of 5 
EBER‐positive cases had a pretreatment plasma EBV DNA 
level ≥ 3.0 log10 copies/mL, high pretreatment plasma EBV 
DNA was also detected in 12/37 tumor EBER‐negative 
DLBCLs, raising the possibility that plasma EBV DNA may 
not be tumor‐derived in many DLBCL cases.
T A B L E  2  Clinical characteristics of HIV‐positive patients with DLBCL stratified by pretreatment plasma EBV DNA level
 
All HIV‐positive DLBCL
HIV‐positive patients with tumor EBV quadruple 
negative DLBCL
n
EBV log10 <  
3.0 copies/mL 
(n = 15)
EBV log10 >  
3.0 copies/mL 
(n = 10)
P 
value n
EBV log10 < 3.0 
copies/mL 
(n = 8)
EBV 
log10 > 3.0 cop-
ies/mL (n = 7)
P 
value
Median survival (days) 25 1534 16 .005 15 1391 15 .01
Death within 100 d, n (%) 25 0 (0) 7 (70) .0002 15 0 (0) 5 (33) .007
Age median years, (range) 25 47.2 (30.3‐63.2) 44.5 (24.1‐53.6) .16 15 49.3 (30.3‐60.1) 44.6 (32.8‐49.9) .09
M:F 25 11:4 8:2 1.0 15 6:2 5:2 1
ECOG PS > 2, n (%) 25 1 (7) 7 (70) .002 15 1 (13) 5 (71) .04
Ann Arbor stage IV, n (%) 25 4 (27) 7 (70) .049 15 2 (25) 4 (57) .31
IPI > 3, n (%) 24 2 (14) 5 (50) .09 15 1 (13) 2 (29) .57
Age adjusted IPI > 3, n (%) 24 1 (7) 4 (40) .12 15 1 (13) 2 (29) .57
Lactate dehydrogenase 
ratio (Patient:ULN), 
mean ± SD
24 2.0 ± 1.5 4.8 ± 4.4 .02 15 2.5 ± 2.1 5.1 ± 5.2 .18
Lactate dehydrogenase 
level greater than ULN, 
n (%)
24 12 (86) 9 (90) 1 15 7 (88) 6 (86) 1
Time since HIV diagnosis, 
years, mean ± SD
23 3.0 ± 4.6 2.8 ± 3.4 .79 14 2.5 ± 3.4 1.3 ± 2.4 .82
CD4 count, cells × 109/L, 
mean ± SD
25 197 ± 158 155 ± 161 .20 15 177 ± 110 189 ± 184 .54
HIV viral load at diag-
nosis, log10 copies/µL, 
mean ± SD
25 2.4 ± 2.4 2.5 ± 2.4 .90 15 1.8 ± 1.7 2.1 ± 2.1 .89
ART naive (<3 mo) at diag-
nosis, n (%)
25 7 (47) 5 (50) 1.0 15 3 (38) 5 (71) .31
White blood cell count, 
109/L, mean ± SD
25 5.5 ± 15 6.5 ± 2.6 .29 15 6 0 ± 1.2 7.5 ± 2.5 .14
Abbreviations: ART, antiretroviral therapy; DLBCL, diffuse large B‐cell lymphoma; EBV, Epstein‐Barr virus; ECOG, Eastern Cooperative Oncology Group (ECOG); 
HIV, human immunodeficiency virus; IPI, International Prognostic Index; SD, standard deviations; ULN, upper limit of normal
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To assess other potential sources of plasma EBV DNA in 
patients with tumor EBER‐negative DLBCL, we also eval-
uated EBER staining in background, non‐neoplastic lym-
phocytes. Rare non‐neoplastic EBER‐positive lymphocytes 
were identified in 6 tumor EBV‐negative DLBCLs, in each 
case representing <1% of all lymph node cells. Cases with 
non‐neoplastic EBER‐positive lymphocytes were no more 
likely than cases without non‐neoplastic EBER‐positive lym-
phocytes to have a plasma EBV DNA level above the assay's 
validated limit of detection or ≥3.0 log10 copies/mL (P = .64 
and .66, respectively).
3.4 | Evaluation of tumor EBV status 
by orthogonal methods
The existence of rigorous pathology protocols in the KCH 
Pathology Laboratory, along with confirmation of RNA 
preservation in 42/44 cases, decreases the likelihood of false 
negative EBER ISH staining in this cohort. To independently 
confirm EBV status in the DLBCL, we used two IHC stains, 
LMP1 (latent membrane protein 1) and EBNA1 (Epstein‐Barr 
nuclear antigen 1). LMP1 and EBNA1 are co‐expressed with 
EBER in EBV's type II and III latency programs, which are 
typically observed in DLBCL.24,25 As such, these stains pro-
vided an orthogonal method of EBV detection. Insufficient 
tissue remained for testing in 5 cases, leaving 20 cases of 
HIV‐positive DLBCL for evaluation, 18 of which had an in-
terpretable EBER stain for comparison. LMP1/EBNA1 re-
sults in tumor cells were concordant with EBER ISH in 17/18 
cases (95%). The lone discordant case (patient 9) exhibited 
positive EBER staining but was negative for LMP1/EBNA1.
To further exclude falsely negative EBV detection in HIV‐
associated DLBCL cases in our cohort, we next attempted to 
evaluate EBV status by real‐time qPCR performed on FFPE 
tissue scrolls (Table 3). Tissue EBV qPCR was concordant 
with EBER ISH results in 18/18 cases and with LMP1/
EBNA1 IHC in 18/20 cases. Both cases with discordant 
qPCR and LMP1/EBNA1 staining results were qPCR posi-
tive and stain negative. One of these cases ( patient 9) was 
also EBER ISH positive, as mentioned above. In the other, 
EBER ISH results were uninterpretable due to failed RNA 
preservation (patient 5).
F I G U R E  2  Morphologic findings 
and EBER stains in representative DLBCL 
from HIV‐positive patients in Malawi. 
Representative hematoxylin & eosin 
stained sections (A,C,E) and EBER in situ 
hybridization results (B,D,F) of DLBCL 
from HIV‐positive patients in Malawi. 
(A,B) Tumor EBER‐positive; (C,D) tumor 
EBER‐negative with undetectable plasma 
EBV; (E,F) tumor EBER‐negative with 
plasma EBV >3.0 log10 copies/mL
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3.5 | Pretreatment plasma EBV and survival 
in HIV‐positive, tumor EBV negative cases
15 of 25 (60%) cases of HIV‐associated DLBCL in this co-
hort were negative by all four tissue‐based methods used to 
detect EBV in this study (EBER ISH, LMP1 IHC, EBNA1 
IHC, Tissue PCR). We refer to these cases as “tumor EBV‐
quadruple‐negative” in order to highlight that there is no 
evidence to indicate that EBV is present in the neoplas-
tic cells in these lymphomas (Table 3). Nevertheless, 7 
of 15 (47%) tumor EBV‐quadruple‐negative lymphomas 
were from patients with a high pretreatment plasma EBV 
DNA level, favoring the conclusion that plasma EBV is 
not tumor‐derived in these individuals. Notably, even in 
these tumor EBV quadruple negative cases, a high pretreat-
ment plasma EBV DNA level remained associated with 
shorter OS (Figure 1D) (P = .014, hazard ratio = 4.1 with 
95%CI 1.0‐16.4). In general, clinical features were similar 
in tumor EBV‐quadruple‐negative patients compared to the 
full HIV‐positive cohort (Table 2).
4 |  DISCUSSION
Plasma EBV has been studied intensely for its clinical util-
ity as a predictive or prognostic biomarker in EBV‐driven 
lymphoma.26,27 In SSA, this biomarker has been most exten-
sively evaluated in endemic Burkitt lymphoma and classic 
T A B L E  3  Tumor EBV status evaluated by multiple methods
Patient 
number
Pretreatment 
plasma EBV 
≥3.0 EBER ISH
LMP1 
IHC
EBNA1 
IHC
Tissue 
EBV 
PCR
Tumor 
EBV 
quadruple 
negative LYM
ISH/IHC 
concordant
EBER/
PCR con-
cordant  
1 NO NEG NEG NEG NEG YES 5 YES YES 1
2 NO NEG NEG NEG NEG YES 9 YES YES 2
3 NO NEG QNS QNS QNS N/A 24 QNS QNS  
4 NO NEG NEG NEG NEG YES 34 YES YES 3
5 NO Uninterpretable NEG NEG POS NO 44 Unint.    
6 NO NEG NEG NEG NEG YES 86 YES Equivocal  
7 NO NEG QNS QNS QNS N/A 116 QNS QNS  
8 NO NEG QNS QNS QNS N/A 127 QNS QNS  
9 NO POS NEG NEG POS NO 243 NO    
10 NO NEG NEG NEG NEG YES 302 YES YES 4
11 NO NEG QNS QNS QNS N/A 15 QNS QNS  
12 NO NEG NEG NEG NEG YES 145 YES YES 5
13 NO NEG NEG NEG NEG YES 159 YES YES 6
14 NO NEG NEG NEG NEG YES 256 YES YES 7
15 NO NEG QNS QNS QNS N/A 81 QNS QNS  
16 YES NEG NEG NEG NEG YES 1 YES YES 8
17 YES NEG NEG NEG NEG YES 192 YES Equivocal  
18 YES NEG NEG NEG NEG YES 204 YES YES 9
19 YES NEG NEG NEG NEG YES 318 YES YES 10
20 YES NEG NEG NEG NEG YES 153 YES YES 11
21 YES NEG NEG NEG NEG YES 202 YES YES 12
22 YES NEG NEG NEG NEG YES 154 YES YES 13
23 YES Uninterpretable POS POS POS NO 121 Unint.    
24 YES POS POS POS POS NO 313 YES    
25 YES NEG (<10%) NEG 
(<10%)
NEG (< 
10%)
NEG NOa 282 YES YES 14
Note: “Uninterpretable” indicates that RNA was inadequately preserved for interpretation of EBER stain.
Abbreviations: EBER, Epstein‐Barr encoded RNA; EBNA1, Epstein‐Barr nuclear antigen 1; EBV, Epstein‐Barr virus; IHC, immunohistochemistry; ISH, in situ 
hybridization; LMP1, latent membrane protein 1; NEG, negative; PCR, polymerase chain reaction; POS, positive; QNS, quantity not sufficient for testing.
aDenotes that the case was classified as not “tumor EBV quadruple negative” due to the small percentage of tumor cells (<10%) positive by EBER, LMP1, and 
EBNA1 stains. 
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Hodgkin lymphoma, both of which are EBV positive in most 
cases.14,15,17,18 Plasma EBV is also a promising lymphoma 
marker in HIV‐positive patients,28 though its utility has been 
primarily explored in patients with EBV‐positive tumors.
We sought to explore the prognostic utility of plasma EBV 
in DLBCL in Malawi. This question is of particular rele-
vance for low‐income countries, which have a high incidence 
of DLBCL, but do not have advanced capabilities like PET 
scans, that are routinely used for DLBCL risk stratification 
in high‐income countries. Measuring plasma viral loads is 
readily implementable in low‐resource settings, especially 
given that existing laboratory capacity has been developed 
to support HIV RNA monitoring in public sector ART pro-
grams. Although high pretreatment plasma EBV DNA has 
been reported in patients with EBER‐negative DLBCL,29,30 
these earlier studies excluded HIV‐positive patients. Here, 
we extend those observations to HIV‐infected individuals 
in Malawi and further show that a high pretreatment plasma 
EBV DNA level is associated with poor overall survival in 
HIV‐positive, tumor EBV‐negative patients.
More than 90% of the world's population is estimated to be 
infected with EBV,31-34 and once infected, EBV persists as a 
latent infection for the remainder of an individual's lifetime.35 
Latently infected cells are rare in normal individuals, represent-
ing fewer than 1 in 10,000 peripheral blood leukocytes.36 As a 
result, EBV DNA is typically undetectable or present only at a 
very low level in the plasma of normal adults.27,37,38 In patients 
with EBV‐driven malignancies, particularly in the post‐trans-
plant setting, plasma EBV may rise as a ctDNA marker.39-42 In 
contrast, detection of high plasma EBV among patients in our 
cohort with EBV tumor‐negative DLBCL strongly suggests 
that the virus is derived from non‐tumor cells.
However, from this small study, it is not possible to deter-
mine underlying mechanisms for poor outcomes in patients 
with a high pretreatment plasma EBV DNA level. Our find-
ings are reminiscent of cytomegalovirus (CMV) reactivation 
being associated with worse outcomes in critically ill pa-
tients.43,44 Analogously, EBV reactivation in nontumor cells 
of HIV‐positive patients with DLBCL could reflect underly-
ing illness or immune dysfunction not reflected in standard 
CD4 count assessment. This interpretation is supported by 
the observation that HIV‐positive patients with high pretreat-
ment plasma EBV DNA levels were more likely to have an 
ECOG performance status ≥2, with a similar trend persisting 
in tumor EBV‐quadruple‐negative DLBCL. It is also possible 
that EBV reactivation in nontumor cells directly contributes 
to worse outcomes for these patients, perhaps by redirecting 
an already impaired immune response in HIV‐infected pa-
tients. Finally, although we have evaluated tumor EBV status 
by multiple, independent methods, it is possible that some 
quadruple‐negative cases are EBV‐driven, despite negative 
ISH, IHC, and PCR studies.
To our knowledge, there are no prior studies explor-
ing the prognostic significance of plasma EBV levels in 
HIV‐positive patients with tumor EBV‐negative DLBCL. 
However, there have been two prior publications showing 
that high plasma EBV DNA is associated with inferior out-
comes in tumor EBV‐negative DLBCL in HIV‐negative 
patients.29,30 In our cohort, we did not observe differences 
in OS related to plasma EBV measurement in HIV‐neg-
ative patients, although interpretation may be limited by 
the relatively small number of HIV‐negative individuals in 
our cohort. Interestingly, a recent study demonstrated that 
the presence of EBV‐positive, non‐neoplastic bystander 
cells are associated with increased IPI score and decreased 
OS in patients with tumor EBV‐negative DLBCL, though 
HIV status was not reported.45 Additionally, studies from 
The Cancer Genome Atlas found the tumor immune mi-
croenvironment was altered significantly by EBV‐positive 
bystander cell infiltration in HIV‐negative solid tumors,46 
suggesting that EBV reactivation in nontumor cells may in-
fluence tumor biology.
The primary limitation of the current study is the rela-
tively small sample size, particularly for tumor EBV‐quadru-
ple‐negative cases. Given these small numbers, multivariate 
analyses were not possible. Of note, we recently validated a 
real‐time plasma EBV DNA assay in Malawi and hope to fur-
ther replicate these initial observations in a larger cohort of 
patients.
Accurate risk stratification of DLBCL is challenging in 
SSA and other low‐income countries, where there is often no 
capacity for cytogenetic or immunophenotypic characteriza-
tion, sequencing studies, or cell‐of‐origin classification. The 
development of blood‐ and plasma‐based molecular diagnos-
tic tests hold promise in this setting, particularly as up‐front 
capital equipment costs decline. Many centers in SSA have 
already developed infrastructure for PCR‐based viral load as-
says, demonstrating that these technologies are highly imple-
mentable in low‐resource settings. Our experience with EBV 
measurement in Malawi suggests that this virus may also be an 
attractive target for blood‐based molecular assay development 
in SSA to improve outcomes across diverse lymphoma sub-
types. Intriguingly, this single highly implementable biomarker 
might help identify patients with EBV‐positive lymphomas at 
highest risk for lymphoma relapse or progression as suggested 
by our previous work,10,11 as well as patients with EBV‐neg-
ative DLBCL at highest risk for early death, as suggested by 
these new analyses.
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